

Madrid, February 23, 2026

LABIANA HEALTH, S.A. (“**Labiana** Health” or the “Company”), in compliance with the provisions of Article 228 of Law 6/2023 of March 17 on Securities Markets and Investment Services, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, on information to be provided by companies listed on that segment, hereby makes public the following:

OTHER RELEVANT INFORMATION

Following on from the communication of "inside information" dated February 18, 2026, we hereby announce that today the Official Gazette of the Mercantile Registry has published the announcement of the capital increase with preemptive subscription rights approved by the Company's Board of Directors on February 18, 2026.

Consequently, the Company's shareholders (other than the Company itself) who have acquired their shares up to and including 11:59 p.m. (CET) today will receive one preemptive subscription right for each share they hold.

The following is a schedule of certain important dates in relation to the capital increase:

Preemptive Subscription Period and request for additional shares:	From February 24, 2026, to March 9, 2026
Preferential subscription rights trading period:	From March 2, 2026, to March 9, 2026
Additional Share Allocation Period:	March 13, 2026
Discretionary Allocation Period:	From March 14, 2026, to March 18, 2026, without prejudice to the company's right to extend or terminate it at any time.
Payment for newly subscribed shares:	March 19, 2026

In compliance with the provisions of Circular 3/2020 of the BME MTF Equity, it is expressly stated that the information communicated herein has been prepared under the sole responsibility of the Company and its administrators.

Mr. Manuel Ramos Ortega
Chief Executive Officer
LABIANA HEALTH, S.A.

SECTION TWO - Legal notices and announcements

CAPITAL INCREASE

543 LABIANA HEALTH, S.A.

In compliance with the provisions of Articles 304 and 503 (in relation to the thirteenth additional provision) of the revised text of the Capital Companies Act, approved by Royal Legislative Decree 1/2010, of July 2, it is hereby announced that the Board of Directors of Labiana Health, S.A. (Labiana or the company), at its meeting held on February 18, 2026, has agreed, under the authorization granted by the company's General Shareholders' Meeting held on June 26, 2025, under item seven of its agenda, to increase the company's share capital through cash contributions and with recognition of preemptive subscription rights (the capital increase).

The most relevant terms and conditions of the capital increase are detailed below:

1.- Amount and type of issue of the capital increase.- The maximum nominal amount of the capital increase is €126,800 and is carried out through the issue and circulation of up to 1,268,000 new ordinary shares of the company, with a nominal value of €0.10 each, of the same class and series as the company's currently outstanding shares, represented by book entries (the new shares), whose accounting records will be attributed to Sociedad de Gestión de los Sistemas de Registro, Compensación y Liquidación de Valores, S.A.U. (Iberclear) and its participating entities. The new shares will confer on their holders the same political and economic rights as the company's currently outstanding ordinary shares from the date on which the company declares the capital increase to be subscribed and paid up.

The new shares will be issued with an issue premium of €3.90 per share, representing a total issue premium of €4,945,200 and a unit issue price (nominal value plus issue premium) of €4 per new share, to be paid up in cash. The total effective amount of the capital increase, considering the unit issue price, will be €5,072,000, without prejudice to possible incomplete subscription. €5,072,000, without prejudice to possible incomplete subscription.

2.- Preemptive subscription rights.- The new shares are issued with recognition of the preemptive subscription rights of the company's shareholders (other than the company itself) who have acquired their shares up to the date of publication of this announcement, inclusive (currently scheduled for February 23, 2026), the business day immediately preceding the start of the preemptive subscription period, and whose transactions have been settled within the two business days immediately following (i.e., according to current projections, up to and including February 25, 2026).

It is hereby stated that:

(i) The company has 243,639 treasury shares, to which no preemptive subscription rights would be assigned and which, therefore, have not been taken into account for the purposes of calculating the proportion of preemptive subscription rights necessary for the subscription of a new share referred to below.

(ii) Bluecolt, S.A., represented by Mr. Manuel Ramos Ortega, has waived the

exercise of 3,616 preemptive subscription rights, necessary to balance the capital increase.

In view of the foregoing, and in accordance with Article 304 of the Capital Companies Act, eligible shareholders may exercise their preemptive subscription rights with respect to all issued shares, at a ratio of 10 new shares for every 55 shares of the company currently in circulation that they hold (the exchange ratio). Each share of the company currently in circulation will grant the right to receive one preemptive subscription right.

In order not to suspend the activity of the liquidity provider and to avoid reducing the number of shares without preemptive subscription rights between the date of the capital increase agreement and the date on which the preemptive subscription rights are registered in favor of the entitled shareholders in their respective accounts, Bluecolt, S.A., represented by Mr. Manuel Ramos Ortega, has undertaken to waive the exercise of the preemptive subscription rights necessary for this purpose, so that the exchange ratio remains at the established proportion and the maximum amount of the capital increase is not exceeded.

3.- Preemptive subscription period.- The period during which the company's current shareholders may exercise their preemptive subscription rights (the preemptive subscription period) will begin on the day following the publication of this announcement and will end after 14 calendar days (i.e., expected to be from February 24, 2026, to March 9, 2026, inclusive).

During the preferential subscription period, the company's shareholders and those investors who have acquired preferential subscription rights and are interested in subscribing for new shares must contact the entity participating in Iberclear or the participating entities in whose accounting records such securities are registered, indicating their willingness to exercise, in whole or in part, their preferential subscription rights. Requests made in relation to the exercise of preemptive subscription rights shall be understood to be final, irrevocable, and unconditional and shall entail the subscription of new shares.

The number of new shares that may be subscribed shall, in any case, be a positive whole number, without decimals or fractions, resulting from the application of the exchange ratio.

During the preferential subscription period, eligible shareholders who have exercised all of their preferential subscription rights and investors who acquire preferential subscription rights and exercise them in full may request, at the time of exercising such rights, the subscription of additional shares (additional shares) in the event that, at the end of the preferential subscription period, there are new shares that have not been subscribed (surplus shares).

Unexercised preemptive subscription rights shall automatically expire at the end of the preemptive subscription period.

Subscription rights shall be transferable under the same conditions as the shares from which they derive, in accordance with the provisions of Article 306.2 of the Spanish Companies Act, and the company will request that they be negotiable on the BME Growth trading segment of BME MTF

Equity (BME Growth) trading segment during the last six business days of the preferential subscription period (the trading period), i.e., expected to be from March 2, 2026, to March 9, 2026.

4.- Additional share allocation period.- In the event that, at the end of the preferential subscription period, there are still new shares that have not been subscribed, a period for the allocation of additional shares (the additional share allocation period) will be opened, during which the remaining new shares will be distributed to those holders of preferential subscription rights who have exercised them in full during the preferential subscription period and who have requested to subscribe for new additional shares to those to which they would be entitled by exercising their preferential subscription rights.

If the number of additional shares requested exceeds the remaining shares, the agent designated for this purpose by the company will pro rata the shares in accordance with the following rules:

i. The remaining shares will be allocated proportionally to the volume of additional shares requested, using the percentage that the number of additional shares requested by each applicant represents in relation to the total number of additional shares requested. The number of additional shares to be delivered will be determined by applying this percentage to the total number of remaining shares, rounded down to the nearest whole number.

ii. Any surplus shares that remain unallocated as a result of rounding will be allocated, one by one, to each applicant for additional shares, starting with the applicant who requested the largest number of additional shares, followed by the next applicant in descending order of the number of additional shares requested, until all surplus shares have been allocated.

iii. In the event of a tie in the remaining shares requested, the order of alphabetical surname or company name shall be followed.

5.- Discretionary allocation period.- If, at the end of the preferential subscription period and the additional share allocation period, there are still new shares that have not been subscribed (hereinafter, the difference between the total number of new shares and the sum of those subscribed during the preferential subscription period and the additional share allocation period, the discretionary allocation shares), a discretionary allocation period for those shares (the discretionary allocation period) will begin, during which they may be allocated to those persons or entities that express their interest in subscribing for and paying for them to the company.

The discretionary allocation period will begin on the day after the additional share allocation period begins and will last for five calendar days, without prejudice to the company's right to extend or terminate it at any time.

6.- Provision for incomplete subscription.- The capital increase agreement expressly provides for the possibility of incomplete subscription, so that, in the event that the capital increase is not fully subscribed, the share capital will be increased by the amount of the subscriptions made, in accordance with the provisions of Article 311 of the Capital Companies Act.

7.- Payment.- The par value and issue premium corresponding to the new shares issued in execution of this agreement shall be paid in full by the subscribers through cash contributions under the terms and conditions established in the transaction schedule.

8.- Admission to trading.- The company will apply for the new shares to be admitted to trading on BME Growth. Likewise, the inclusion of the new shares in Iberclear's accounting records will be requested.

Madrid, February 19, 2026. The Secretary of the Board of Directors of Labiana Health, S.A., Mr. Miquel Pujolriu Giménez.

ID: A260006818-1